06:54 AM EDT, 06/10/2024 (MT Newswires) -- Eli Lilly and Company ( LLY ) said Saturday that results from SYNERGY-NASH showed that tirzepatide was superior to placebo for the resolution of metabolic dysfunction-associated steatohepatitis, or MASH.

SYNERGY-NASH is a phase 2 study of 190 patients, with or without type 2 diabetes, evaluating the investigational use of tirzepatide in adults with biopsy-proven MASH with stage 2 or 3 fibrosis.

The company said that while the phase 2 study was not designed to prove that tirzepatide improves fibrosis, it showed that more than half of patients achieved improvement in fibrosis at 52 weeks.

Tirzepatide was also associated with improvements in body weight, blood markers of liver injury, biomarkers of liver fat and inflammation, the company said.

Price: 856.00, Change: +6.01, Percent Change: +0.71